SRNE News and Press, Sorrento Therapeutics Inc. From 08/23/22

Sorrento Therapeutics ( NASDAQ: SRNE ) said that a pivotal study of its candidate abivertinib in non-small cell lung cancer demonstrated an overall response rate of 56.5% . In addition, results showed that 11 patients had complete responses ("CR") for a CR ra...

Abivertinib is a novel third-generation epidermal growth factor receptor (EGFR) inhibitor that irreversibly targets mutant forms of EGFR in advanced NSCLC patients who are resistant to first-line EGFR kinase inhibitor therapies. In this pivotal study conducted in China, matured data o...

Sorrento Therapeutics released its Q2-2022 results. Revenues are down 15% year-on-year with sales from COVISTIX all in Q1-2022. Sorrento has signed a new agreement for the distribution of ZTlido in the Middle East and North Africa. Sorrento will commercialize the Gloperba in t...

U.S. biopharma Sorrento Therapeutics, Inc. ( NASDAQ: SRNE ) announced Friday that the company received regulatory clearance from the China National Medical Products Administration (NMPA) to conduct an early-stage clinical trial for its oral COVID-19 therapy STI-1558 in China. ...

STI-1558, an oral SARS-CoV-2 main protease (M pro ) inhibitor, which can block viral replication, is specifically designed as a standalone treatment of COVID-19 without ritonavir as a booster. Single ascending dose (SAD) portion of the Phase I healthy subject study has been comple...

Sorrento's ( NASDAQ: SRNE ) unit Scilex Holding signed a distribution agreement for its non-opioid pain drug ZTlido with CH Trading Group, for certain territories including Middle East and North Africa. "We are pleased to work with CH Trading to hel...

PALO ALTO, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, today announced the signing of a Product Dist...

30 million lives now covered by one of the largest national PBMs Continue to work with this PBM to access an additional 20 million lives The team continues to work with the national PBM’s and health plans to improve access further during 2022 with a goal to reach 250 millio...

Single ascending dose (SAD) Phase 1 Study completed in Australia with a maximum dose of 2,000 mg. Pharmacokinetics (PK) were dose proportional and PK modeling and preclinical data support a 600 mg twice daily dose. There were no serious AEs (SAEs) or severe TEAEs and the maximum t...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips This article is excerpted from Tom Yeung’s Profit & Protection newsletter dated July 28, 2022. To make sure you don’t miss any of Tom’s picks,  subscribe to his mailing list here . Sourc...